KLK4
Kallikrein-4
Protein Summary
Has a major role in enamel formation (PubMed:15235027). Required during the maturation stage of tooth development for clearance of enamel proteins and normal structural patterning of the crystalline matrix (By similarity). Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. In some tissues its expression is hormonally regulated. The expression pattern of a similar mouse protein in murine developing teeth supports a role for the protein in the degradation of enamel proteins. Several transcript variants encoding different proteins have been found for this gene. [provided by RefSeq, Dec 2014]
- ENST00000431178
- ENSP00000399448
- ENSG00000167749
- EMSP1
- PRSS17
- PSTS
- ARM1
- EMSP
- PSTS
- AI2A1
- EMSP1
- KLK-L1
- PRSS17
- kallikrein
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
gene perturbation | 0.78 | ||
cell type or tissue | 0.65 | ||
protein domain | 0.58 | ||
biological term | 0.54 | ||
cell line | 0.49 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 5175.93 (req: < 5)
Gene RIFs: 64 (req: <= 3)
Antibodies: 265 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 5175.93 (req: >= 5)
Gene RIFs: 64 (req: > 3)
Antibodies: 265 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 7
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 15
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0